About Sarepta Therapeutics
Sarepta Therapeutics is a company based in Cambridge (United States) founded in 1980. It operates as a HealthTech. The company has 1,370 employees as of December 31, 2024. Sarepta Therapeutics has completed 1 acquisition, including Myonexus Therapeutics. Sarepta Therapeutics offers products and services including Gene Therapy Treatments, RNA Platform Solutions, and Gene Editing Therapies. Sarepta Therapeutics operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Alnylam and ATAI, among others.
- Headquarter Cambridge, United States
- Employees 1370 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Sarepta Therapeutics, Inc.
-
Annual Revenue
$1.9 B52.97as on Dec 31, 2024
-
Net Profit
$235.24 M0as on Dec 31, 2024
-
EBITDA
$271.97 M0as on Dec 31, 2024
-
Latest Funding Round
$400 M (USD), Post-IPO
Feb 28, 2020
-
Investors
Morgan Stanley
& 8 more
-
Employee Count
1370
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Sarepta Therapeutics
Sarepta Therapeutics is a publicly listed company on the NASDAQ with ticker symbol SRPT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Sarepta Therapeutics
Sarepta Therapeutics offers a comprehensive portfolio of products and services, including Gene Therapy Treatments, RNA Platform Solutions, and Gene Editing Therapies. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Gene therapies are developed for rare genetic diseases.
RNA technologies are utilized for rare disease treatments.
Gene editing is applied to address rare diseases.
Unlock access to complete
Unlock access to complete
Leadership Team
115 people
Software Development Team
37 people
Senior Team
37 people
Operations Team
33 people
Product Management Team
32 people
Finance and Accounting
22 people
Sales and Marketing
11 people
Legal and Compliance
11 people
Unlock access to complete
Funding Insights of Sarepta Therapeutics
- Total Funding Total Funding
- Total Rounds 8
- Last Round Post-IPO — $400.0M
-
First Round
First Round
(01 Dec 2006)
- Investors Count 9
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2020 | Amount | Post-IPO - Sarepta Therapeutics | Valuation |
investors |
|
| Nov, 2019 | Amount | Post-IPO - Sarepta Therapeutics | Valuation |
investors |
|
| Oct, 2015 | Amount | Post-IPO - Sarepta Therapeutics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Sarepta Therapeutics
Sarepta Therapeutics has secured backing from 9 investors, including institutional investors. Prominent investors backing the company include Morgan Stanley, Credit Suisse and Baird. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Wealth management, investment advisory, and financial services are provided.
|
Founded Year | Domain | Location | |
|
Financial services including wealth management and investment banking are offered by Baird.
|
Founded Year | Domain | Location | |
|
Investment banking firm
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Sarepta Therapeutics
Sarepta Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Myonexus Therapeutics. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Clinical stage gene therapy company developing treatments for Limb-girdle muscular dystrophy (LGMD)
|
2017 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Sarepta Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Sarepta Therapeutics Comparisons
Competitors of Sarepta Therapeutics
Sarepta Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Alnylam and ATAI, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Sarepta Therapeutics
Frequently Asked Questions about Sarepta Therapeutics
When was Sarepta Therapeutics founded?
Sarepta Therapeutics was founded in 1980 and raised its 1st funding round 26 years after it was founded.
Where is Sarepta Therapeutics located?
Sarepta Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
How many employees does Sarepta Therapeutics have?
As of Dec 31, 2024, the latest employee count at Sarepta Therapeutics is 1,370.
What is the annual revenue of Sarepta Therapeutics?
Annual revenue of Sarepta Therapeutics is $1.9B as on Dec 31, 2024.
What does Sarepta Therapeutics do?
Sarepta Therapeutics is engaged in the development of precision genetic medicines aimed at treating rare diseases. The company specializes in gene therapy, RNA technologies, and gene editing platforms. Focus areas include Duchenne muscular dystrophy, limb-girdle muscular dystrophy, and Charcot-Marie-Tooth disease. Solutions are engineered to transform genetic understanding into effective treatments. Efforts are made to shorten drug development timelines and build significant gene therapy manufacturing capacity. Access and reimbursement models for innovative treatments are also rethought. The mission is centered on reclaiming futures impacted by rare diseases through relentless scientific advancement.
Who are the top competitors of Sarepta Therapeutics?
Sarepta Therapeutics's top competitors include Moderna, Spark Therapeutics and BridgeBio.
What products or services does Sarepta Therapeutics offer?
Sarepta Therapeutics offers Gene Therapy Treatments, RNA Platform Solutions, and Gene Editing Therapies.
Is Sarepta Therapeutics publicly traded?
Yes, Sarepta Therapeutics is publicly traded on NASDAQ under the ticker symbol SRPT.
How many acquisitions has Sarepta Therapeutics made?
Sarepta Therapeutics has made 1 acquisition, including Myonexus Therapeutics.
Who are Sarepta Therapeutics's investors?
Sarepta Therapeutics has 9 investors. Key investors include Morgan Stanley, Credit Suisse, Baird, HHS, and Needham.
What is Sarepta Therapeutics's ticker symbol?
The ticker symbol of Sarepta Therapeutics is SRPT on NASDAQ.